Summary

Global clinical laboratory services market is projected to register a CAGR of 7.2% in the forecast period of 2021 to 2028. The new market report contains data for the historic year 2019, the base year of calculation is 2020 and the forecast period is 2021 to 2028

Market Segmentation:
Global Clinical Laboratory Services Market, By Specialty (Clinical Chemistry Testing, Hematology Testing, Microbiology Testing, Immunology Testing, Drugs of Abuse Testing, Cytology Testing and Genetic Testing), Provider (Independent & Reference Laboratories, Hospital-Based Laboratories and Nursing and Physician Office-Based Laboratories), Application (Drug Discovery Related Services, Drug Development Related Services, Bioanalytical & Lab Chemistry Services, Toxicology Testing Services, Cell & Gene Therapy Related Services, Preclinical & Clinical Trial Related Services and Other Clinical Laboratory Services), Service Type (Routine Testing Services, Esoteric Services And Anatomic Pathology Services), Country (U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Rest of Europe, Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, and Rest of Middle East and Africa) Industry Trends and Forecast To 2028

Some of the major factors contributing to the growth of the global clinical laboratory services market are:

• Rising infectious diseases worldwide
• Advancement in clinical diagnostic methods


Market Players:

The key market players for global clinical laboratory services market are listed below:

• Mayo Foundation for Medical Education and Research (MFMER)
• Laboratory Corporation of America Holding
• Quest Diagnostics Incorporated
• DaVita Inc.
• Eurofins Scientific
• UNILABS
• SYNLAB International GmbH
• H.U. Groups Holdings, Inc.
• Sonic Healthcare
• ACM Global Laboratories
• Amedes Holding GmbH
• LifeLabs
• Abbott
• Charles River
• Siemens Healthineers AG
• BioReference Laboratories, Inc. (A subsidiary of Opko Health, Inc.)
• NeoGenomics Laboratories, Inc.
• KingMed Diagnostics
• Genomic Health
• ARUP Laboratories

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 INTRODUCTION 31
1.1 OBJECTIVES OF THE STUDY 31
1.2 MARKET DEFINITION 31
1.3 OVERVIEW OF GLOBAL CLINICAL LABORATORY SERVICES MARKET 31
1.4 LIMITATIONS 33
1.5 MARKETS COVERED 33
2 MARKET SEGMENTATION 35
2.1 MARKETS COVERED 35
2.2 GEOGRAPHICAL SCOPE 36
2.3 YEARS CONSIDERED FOR THE STUDY 37
2.4 CURRENCY AND PRICING 37
2.5 DBMR TRIPOD DATA VALIDATION MODEL 38
2.6 MULTIVARIATE MODELLING 41
2.7 PRODUCT TYPE LIFELINE CURVE 42
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 43
2.9 DBMR MARKET POSITION GRID 44
2.10 MARKET APPLICATION COVERAGE GRID 45
2.11 VENDOR SHARE ANALYSIS 47
2.12 SECONDARY SOURCES 48
2.13 ASSUMPTIONS 48
3 EXECUTIVE SUMMARY 50
4 PREMIUM INSIGHTS 52
5 OVERVIEW OF ADJACENT BUSINESS 55
5.1 IMPACT OF POINT OF CARE TESTING MARKET ON CLINICAL LABORATORY TESTING MARKET 55
5.2 IMPACT OF BIOMETRIC SCREENING MARKET ON CLINICAL LABORATORY TESTING MARKET 56
5.3 IMPACT OF MOLECULAR DIAGNOSTICS MARKET ON CLINICAL LABORATORY TESTING MARKET 56
5.4 CONCLUSION 56
6 GLOBAL CLINICAL LABORATORY SERVICES MARKET: REGULATIONS 58
6.1 REGULATION IN THE U.S. 58
6.2 REGULATION IN EUROPE 59
6.3 REGULATIONS IN THAILAND 59
6.4 REGULATIONS IN DUBAI 60
6.5 REGULATIONS IN INDIA 60
6.6 REGULATIONS IN CHINA 61
6.7 REGULATIONS IN JAPAN 61
6.8 REGULATIONS IN SOUTH AFRICA 61
7 GLOBAL CLINICAL LABORATORY SERVICES MARKET: REIMBURSEMENTS 63
7.1 REIMBURSEMENT IN THE U.S. FOR CLINICAL LABORATORY SERVICES 63
7.2 REIMBURSEMENT IN INDIA FOR CLINICAL LABORATORY SERVICES 64
7.3 REIMBURSEMENT IN JAPAN FOR CLINICAL LABORATORY SERVICES 64
7.4 REIMBURSEMENT IN EUROPE FOR CLINICAL LABORATORY SERVICES 64
7.5 REIMBURSEMENT IN SOUTH AFRICA FOR CLINICAL LABORATORY SERVICES 65
8 MARKET OVERVIEW 66
8.1 DRIVERS 68
8.1.1 RISE IN INFECTIOUS DISEASES WORLDWIDE 68
8.1.2 ADVANCEMENT IN CLINICAL DIAGNOSTIC METHODS 69
8.1.3 DEVELOPMENT IN DATABASE MANAGEMENT TOOLS AND WIDE ACCEPTANCE OF POINT-OF-CARE (POC) TESTING SOLUTIONS 70
8.1.4 RISE IN DEMAND FOR EARLY AND ACCURATE DISEASE DIAGNOSIS 70
8.1.5 INCREASE IN APPLICATION OF HIGH-THROUGHPUT ASSAYS 71
8.2 RESTRAINTS 72
8.2.1 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 72
8.2.2 STRICT REGULATORY POLICIES 73
8.3 OPPORTUNITIES 74
8.3.1 INCREASE IN ADOPTION OF DIGITAL PATHOLOGY PLATFORMS 74
8.3.2 RISE IN PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS 75
8.3.3 INCREASE IN AWARENESS ABOUT DIAGNOSIS AND TREATMENT OF THE DISEASE 76
8.3.4 STRATEGIC INITIATIVES BY MARKET PLAYERS 77
8.4 CHALLENGES 78
8.4.1 INACCURATE RESULTS OF TESTS 78
8.4.2 INADEQUATE REIMBURSEMENTS POLICIES 79
9 IMPACT OF COVID-19 ON GLOBAL CLINICAL LABORATORY SERVICES MARKET 80
9.1 PRICE IMPACT 80
9.2 IMPACT ON DEMAND 80
9.3 IMPACT ON SUPPLY CHAIN 81
9.4 STRATEGIC DECISIONS FOR MANUFACTURERS 82
9.5 CONCLUSION 82
 
10 GLOBAL CLINICAL LABORATORY SERVICES MARKET, BY SERVICE TYPE 84
10.1 OVERVIEW 85
10.2 ROUTINE TESTING SERVICES 88
10.2.1 ROUTINE CHEMISTRY TESTING 89
10.2.2 ROUTINE HEMATOLOGY TESTING 89
10.2.3 URINALYSIS TESTING 89
10.2.4 SUBSTANCE ABUSE TESTING 89
10.2.5 OTHERS 89
10.3 ESOTERIC SERVICES 89
10.4 ANATOMIC PATHOLOGY SERVICES 90
10.4.1 CYTOLOGY TESTING 91
10.4.2 DIAGNOSTIC SURGICAL PATHOLOGY TESTING 91
10.4.3 AUTOPSY PATHOLOGY 91
10.4.4 OTHERS 91
11 GLOBAL CLINICAL LABORATORY SERVICES MARKET, BY SPECIALTY 92
11.1 OVERVIEW 93
11.2 CLINICAL CHEMISTRY TESTING 96
11.2.1 ROUTINE CHEMISTRY TESTING 97
11.2.2 THERAPEUTIC DRUG MONITORING (TDM) TESTING 97
11.2.3 SPECIALIZED CHEMISTRY TESTING 97
11.2.4 OTHER CLINICAL CHEMISTRY TESTING 97
11.3 HEMATOLOGY TESTING 98
11.3.1 ROUTINE HEMATOLOGY TESTING 99
11.3.2 SPECIALIZED HEMATOLOGY TESTING 99
11.3.3 COAGULATION TESTING 99
11.4 MICROBIOLOGY TESTING 99
11.4.1 INFECTIOUS DISEASE TESTING 100
11.4.2 TRANSPLANT DIAGNOSTIC TESTING 100
11.4.3 OTHER MICROBIOLOGY TESTING 100
11.5 IMMUNOLOGY TESTING 100
11.6 DRUGS OF ABUSE TESTING 101
11.7 CYTOLOGY TESTING 102
11.8 GENETIC TESTING 102
12 GLOBAL CLINICAL LABORATORY SERVICES MARKET, BY PROVIDER 104
12.1 OVERVIEW 105
12.2 HOSPITAL-BASED LABORATORIES 108
12.3 INDEPENDENT & REFERENCE LABORATORIES 108
12.4 NURSING AND PHYSICIAN OFFICE-BASED LABORATORIES 109
13 GLOBAL CLINICAL LABORATORY SERVICES MARKET, BY APPLICATION 110
13.1 OVERVIEW 111
13.2 BIOANALYTICAL & LAB CHEMISTRY SERVICES 114
13.3 DRUG DEVELOPMENT RELATED SERVICES 114
13.4 DRUG DISCOVERY RELATED SERVICES 115
13.5 TOXICOLOGY TESTING SERVICES 116
13.6 CELL & GENE THERAPY RELATED SERVICES 116
13.7 PRECLINICAL & CLINICAL TRIAL RELATED SERVICES 117
13.8 OTHER CLINICAL LABORATORY SERVICES 118
14 GLOBAL CLINICAL LABORATORY SERVICES MARKET, BY REGION 119
14.1 OVERVIEW 120
14.2 NORTH AMERICA 125
14.2.1 U.S. 132
14.2.2 CANADA 135
14.2.3 MEXICO 138
14.3 EUROPE 142
14.3.1 GERMANY 149
14.3.2 U.K. 152
14.3.3 ITALY 155
14.3.4 FRANCE 158
14.3.5 SPAIN 161
14.3.6 RUSSIA 164
14.3.7 NETHERLANDS 167
14.3.8 SWITZERLAND 170
14.3.9 BELGIUM 173
14.3.10 TURKEY 176
14.3.11 REST OF EUROPE 179
14.4 ASIA-PACIFIC 180
14.4.1 CHINA 187
14.4.2 JAPAN 190
14.4.3 SOUTH KOREA 193
14.4.4 INDIA 196
14.4.5 AUSTRALIA 199
14.4.6 SINGAPORE 202
14.4.7 THAILAND 205
14.4.8 MALAYSIA 208
14.4.9 INDONESIA 211
14.4.10 PHILIPPINES 214
14.4.11 REST OF ASIA-PACIFIC 217
14.5 SOUTH AMERICA 218
14.5.1 BRAZIL 225
14.5.2 ARGENTINA 228
14.5.3 REST OF SOUTH AMERICA 231
14.6 MIDDLE EAST & AFRICA 231
14.6.1 SOUTH AFRICA 238
14.6.2 SAUDI ARABIA 241
14.6.3 U.A.E. 244
14.6.4 EGYPT 247
14.6.5 ISRAEL 250
14.6.6 REST OF MIDDLE EAST & AFRICA 253
15 GLOBAL CLINICAL LABORATORY SERVICES MARKET: COMPANY LANDSCAPE 254
15.1 COMPANY SHARE ANALYSIS: GLOBAL 254
15.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 255
15.3 COMPANY SHARE ANALYSIS: EUROPE 256
15.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 257
16 SWOT ANALYSIS 258
17 COMPANY PROFILE 259
17.1 LABORATORY CORPORATION OF AMERICA 259
17.1.1 COMPANY SNAPSHOT 259
17.1.2 REVENUE ANALYSIS 260
17.1.3 COMPANY SHARE ANALYSIS 260
17.1.4 SERVICE PORTFOLIO 261
17.1.5 RECENT DEVELOPMENTS 261
17.2 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH 263
17.2.1 COMPANY SNAPSHOT 263
17.2.2 COMPANY SHARE ANALYSIS 263
17.2.3 SERVICE PORTFOLIO 263
18.1.1 RECENT DEVELOPMENTS 267
18.2 DAVITA INC. 268
18.2.1 COMPANY SNAPSHOT 268
18.2.2 REVENUE ANALYSIS 268
18.2.3 COMPANY SHARE ANALYSIS 269
18.2.4 SERVICE PORTFOLIO 269
18.2.5 RECENT DEVELOPMENTS 269
 
18.3 QUEST DIAGNOSTICS INCORPORATED 271
18.3.1 COMPANY SNAPSHOT 271
18.3.2 REVENUE ANALYSIS 272
18.3.3 COMPANY SHARE ANALYSIS 272
18.3.4 SERVICE PORTFOLIO 273
18.3.5 RECENT DEVELOPMENTS 273
18.4 SONIC HEALTHCARE 275
18.4.1 COMPANY SNAPSHOT 275
18.4.2 REVENUE ANALYSIS 276
18.4.3 SERVICE PORTFOLIO 276
18.4.4 RECENT DEVELOPMENTS 277
18.5 ABBOTT 278
18.5.1 COMPANY SNAPSHOT 278
18.5.2 REVENUE ANALYSIS 279
18.5.3 PRODUCT PORTFOLIO 279
18.5.4 RECENT DEVELOPMENTS 280
18.6 ACM GLOBAL LABORATORIES 282
18.6.1 COMPANY SNAPSHOT 282
18.6.2 SERVICE PORTFOLIO 282
18.6.3 RECENT DEVELOPMENTS 283
18.7 AMEDES HOLDING GMBH 284
18.7.1 COMPANY SNAPSHOT 284
18.7.2 SERVICE PORTFOLIO 284
18.7.3 RECENT DEVELOPMENT 285
18.8 ARUP LABORATORIES 286
18.8.1 COMPANY SNAPSHOT 286
18.8.2 SERVICE PORTFOLIO 286
18.8.3 RECENT DEVELOPMENTS 287
18.9 BIOREFERENCE LABORATORIES, INC. (A SUBSIDIARY OF OPKO HEALTH, INC.) 288
18.9.1 COMPANY SNAPSHOT 288
18.9.2 REVENUE ANALYSIS 288
18.9.3 SERVICE PORTFOLIO 289
18.9.4 RECENT DEVELOPMENTS 289
18.10 CHARLES RIVER 291
18.10.1 COMPANY SNAPSHOT 291
18.10.2 REVENUE ANALYSIS 291
18.10.3 SERVICE PORTFOLIO 292
18.10.4 RECENT DEVELOPMENTS 293
 
18.11 EUROFINS SCIENTIFIC 295
18.11.1 COMPANY SNAPSHOT 295
18.11.2 REVENUE ANALYSIS 295
18.11.3 SERVICE PORTFOLIO 296
18.11.4 RECENT DEVELOPMENTS 296
18.12 GENOMIC HEALTH 297
18.12.1 COMPANY SNAPSHOT 297
18.12.2 REVENUE ANALYSIS 297
18.12.3 PRODUCT PORTFOLIO 298
18.12.4 RECENT DEVELOPMENTS 298
18.13 H.U. GROUP HOLDINGS, INC. 299
18.13.1 COMPANY SNAPSHOT 299
18.13.2 REVENUE ANALYSIS 300
18.13.3 SERVICE PORTFOLIO 300
18.13.4 RECENT DEVELOPMENTS 301
18.14 KINGMED DIAGNOSTICS 302
18.14.1 COMPANY SNAPSHOT 302
18.14.2 SERVICE PORTFOLIO 302
18.14.3 RECENT DEVELOPMENTS 302
18.15 LIFELABS 304
18.15.1 COMPANY SNAPSHOT 304
18.15.2 SERVICE PORTFOLIO 304
18.15.3 RECENT DEVELOPMENTS 304
18.16 NEOGENOMICS LABORATORIES, INC. 306
18.16.1 COMPANY SNAPSHOT 306
18.16.2 REVENUE ANALYSIS 306
18.16.3 SERVICE PORTFOLIO 307
18.16.4 RECENT DEVELOPMENTS 307
18.17 SIEMENS HEALTHINEERS GMBH 308
18.17.1 COMPANY SNAPSHOT 308
18.17.2 REVENUE ANALYSIS 308
18.17.3 SERVICE PORTFOLIO 309
18.17.4 RECENT DEVELOPMENTS 309
18.18 ,SYNLAB INTERNATIONAL GMBH (A SUBSIDIARY OF SYNLAB AG) 310
18.18.1 COMPANY SNAPSHOT 310
18.18.2 REVENUE ANALYSIS 310
18.18.3 SERVICE PORTFOLIO 311
18.18.4 RECENT DEVELOPMENTS 311
 
18.19 NILABS 314
18.19.1 COMPANY SNAPSHOT 314
18.19.2 SERVICE PORTFOLIO 314
18.19.3 RECENT DEVELOPMENTS 315
19 QUESTIONNAIRE 316
20 RELATED REPORTS 320